<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00616785</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000584442</org_study_id>
    <secondary_id>YONSEI-4-2007-0120</secondary_id>
    <nct_id>NCT00616785</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery</brief_title>
  <official_title>Phase II Trial Irinotecan and Cisplatin Induction Chemotherapy Followed by Radiotherapy Concurrently With Etoposide/Cisplatin in Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as irinotecan, cisplatin, and etoposide work in&#xD;
      different ways to stop the growth of tumor cells, either by killing the cells or by stopping&#xD;
      them from dividing. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving&#xD;
      combination chemotherapy together with radiation therapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving combination chemotherapy together&#xD;
      with radiation therapy works in treating patients with stage III non-small cell lung cancer&#xD;
      that cannot be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To evaluate the efficacy of induction chemotherapy comprising irinotecan hydrochloride&#xD;
           and cisplatin in patients with locally advanced, unresectable stage III non-small cell&#xD;
           lung cancer.&#xD;
&#xD;
        -  To evaluate the feasibility of radiotherapy administered concurrently with etoposide and&#xD;
           cisplatin chemotherapy after induction chemotherapy in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To evaluate the toxicity of induction chemotherapy comprising irinotecan hydrochloride&#xD;
           and cisplatin in these patients.&#xD;
&#xD;
        -  To assess whether this induction chemotherapy regimen will improve patient survival when&#xD;
           compared with outcomes from the predecessor study, SWOG-9019.&#xD;
&#xD;
      OUTLINE: Patients receive dose-dense induction chemotherapy comprising irinotecan&#xD;
      hydrochloride IV and cisplatin IV on days 1 and 8. Treatment repeats every 21 days for up to&#xD;
      2 courses.&#xD;
&#xD;
      After completion of induction chemotherapy, patients undergo radiotherapy five days a week&#xD;
      for approximately 7 weeks. Patients receive concurrent chemotherapy comprising cisplatin IV&#xD;
      on days 1, 8, 29, and 36 and etoposide IV on days 1-5 and 29-33.&#xD;
&#xD;
      After completion of study therapy, patients are followed at 6 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2007</start_date>
  <primary_completion_date type="Anticipated">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of local/regional control</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of systemic disease control</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility of radiotherapy administered concurrently with etoposide and cisplatin chemotherapy</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity of irinotecan hydrochloride and cisplatin induction chemotherapy as assessed by NCI CTCAE v3.0</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">41</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)&#xD;
&#xD;
               -  Stage IIIA (N2) or IIIB disease&#xD;
&#xD;
                    -  Pathologic documentation of N2-3 mediastinal lymph nodes is encouraged but&#xD;
                       not required if nodal size is ≥ 1.5 cm in largest diameter&#xD;
&#xD;
                    -  No stage IIIB disease with malignant pleural effusion or superior sulcus&#xD;
                       tumor&#xD;
&#xD;
          -  At least one measurable lesion as defined by Response Evaluation Criteria in Solid&#xD;
             Tumors&#xD;
&#xD;
          -  Unresectable disease&#xD;
&#xD;
          -  No known brain metastasis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  ANC ≥ 1,500/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 g/dL (can be corrected by transfusion)&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Creatinine &lt; 1.5 mg/dL&#xD;
&#xD;
          -  Total bilirubin &lt; 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Transaminases &lt; 3 times ULN&#xD;
&#xD;
          -  Patient compliance and geographic proximity that allow adequate follow up&#xD;
&#xD;
          -  No serious, uncontrolled systemic intercurrent illness (e.g., infections or poorly&#xD;
             controlled diabetes)&#xD;
&#xD;
          -  No history of significant neurological or mental disorder, including seizures or&#xD;
             dementia&#xD;
&#xD;
          -  No other malignancy within the past 5 years except carcinoma in situ of the cervix or&#xD;
             nonmelanoma skin cancer&#xD;
&#xD;
          -  No active cardiac disease not controlled by therapy&#xD;
&#xD;
          -  No myocardial infarction within the past 12 months&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior chemotherapy or radiotherapy for NSCLC&#xD;
&#xD;
          -  No other concurrent systemic chemotherapy, investigational drug, or radiotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joo-Hang Kim, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Yonsei University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yonsei Cancer Center at Yonsei University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joo-Hang Kim, MD</last_name>
      <phone>+82-10-4507-6063</phone>
      <email>kjhang@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <study_first_submitted>February 14, 2008</study_first_submitted>
  <study_first_submitted_qc>February 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2008</study_first_posted>
  <last_update_submitted>February 6, 2009</last_update_submitted>
  <last_update_submitted_qc>February 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2009</last_update_posted>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

